Synergy between Toxoplasma gondii type I ΔGRA17 immunotherapy and PD-L1 checkpoint inhibition triggers the regression of targeted and distal tumors

BACKGROUND: In this study, we hypothesize that the ability of the protozoan Toxoplasma gondii to modulate immune response within the tumor might improve the therapeutic effect of immune checkpoint blockade. We examined the synergetic therapeutic activity of attenuated T. gondii RH ΔGRA17 strain and...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Yu-Chao, Elsheikha, Hany M, Wang, Jian-Hua, Fang, Shuai, He, Jun-Jun, Zhu, Xing-Quan, Chen, Jia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Oncolytic and Local Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8562526/
https://www.ncbi.nlm.nih.gov/pubmed/34725213
http://dx.doi.org/10.1136/jitc-2021-002970

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8562526/
https://www.ncbi.nlm.nih.gov/pubmed/34725213
http://dx.doi.org/10.1136/jitc-2021-002970

Ejemplares similares